LAPTM4A and glioblastoma: In conclusion, we found the high expression and better prognostic and diagnostic value of LAPTM4A in glioma and LGG and GBM subtypes and explored that LAPTM4A most probably promoted glioma progression through EMT or immunosuppression pathways.